文献速递鼻科

度普利尤单抗治疗与内镜鼻窦手术治疗慢性鼻窦炎伴鼻息肉的疗效比较

Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
PubMed 文献 · Int Forum Allergy Rhinol · 2022-01-10

这项回顾性匹配队列研究比较了54例接受度普利尤单抗治疗的慢性鼻窦炎伴鼻息肉(CRSwNP)患者与54例接受功能性内镜鼻窦手术(FESS)的患者,两组均使用局部糖皮质激素。FESS组鼻息肉评分改善更大(5.18 ± 2.01 vs 4.27 ± 1.98,p = 0.02),度普利尤单抗组在鼻外鼻科SNOT-22域评分(4.87 ± 3.91 vs 2.93 ± 4.32,p = 0.02)和嗅觉评分(2.35 ± 2.17 vs 1.48 ± 2.24,p = 0.04)改善更大,总体SNOT-22评分变化无显著差异。

要点

  • FESS组鼻息肉评分改善大于度普利尤单抗组(5.18 ± 2.01 vs 4.27 ± 1.98,p = 0.02)。
  • 度普利尤单抗组鼻外鼻科SNOT-22域评分改善大于FESS组(4.87 ± 3.91 vs 2.93 ± 4.32,p = 0.02)。
  • 度普利尤单抗组SNOT-22嗅觉评分改善大于FESS组(2.35 ± 2.17 vs 1.48 ± 2.24,p = 0.04)。

核心结论

  • 总体而言,根据SNOT-22,两种疗法均能有效减轻CRSwNP患者的症状。
  • 度普利尤单抗组报告嗅觉改善以及咳嗽、后鼻滴涕和浓稠鼻分泌物减少,而FESS组息肉负荷减少更明显。

研究设计与样本

  • 回顾性匹配队列研究,比较54例接受度普利尤单抗治疗的CRSwNP患者与54例接受FESS的CRSwNP患者,两组均使用局部糖皮质激素。
  • 主要终点为鼻息肉评分和总体SNOT-22评分变化,次要终点为SNOT-22域评分和SNOT-22嗅觉评分变化。

主要发现

  • FESS组鼻息肉评分改善为5.18 ± 2.01,度普利尤单抗组为4.27 ± 1.98(p = 0.02)。
  • 总体SNOT-22评分变化无显著差异。
  • 度普利尤单抗组鼻外鼻科SNOT-22域评分改善为4.87 ± 3.91,FESS组为2.93 ± 4.32(p = 0.02)。
  • 度普利尤单抗组SNOT-22嗅觉评分改善为2.35 ± 2.17,FESS组为1.48 ± 2.24(p = 0.04)。
  • 度普利尤单抗组平均随访12.20个月,FESS组平均随访17.90个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outside of SINUS-24 (A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps) and SINUS-52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps), there are limited data on the efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The objective was to compare dupilumab with functional endoscopic sinus surgery (FESS) in patients with CRSwNP by assessing the change in nasal polyp and Sino-Nasal Outcome Test (SNOT-22) scores postintervention. METHODS: A retrospective matched cohort study compared 54 patients who had CRSwNP treated with dupilumab with 54 patients who had CRSwNP treated with FESS; both cohorts were treated with topical corticosteroids. The primary end points were change in nasal polyp score and overall SNOT-22 score. Secondary end points were change in SNOT-22 domain scores and SNOT-22 olfaction score. RESULTS: Patients who underwent FESS had a greater improvement in nasal polyp score (5.18 ± 2.01) compared with patients treated with dupilumab (4.27 ± 1.98, p = 0.02). There was no significant difference in terms of the change in overall SNOT-22 score. Patients treated with dupilumab had greater improvement in the extranasal rhinologic SNOT-22 domain scores (4.87 ± 3.91) compared with patients treated with FESS (2.93 ± 4.32, p = 0.02). There was a greater improvement in the SNOT-22 olfaction scores for patients treated with dupilumab (2.35 ± 2.17) compared with patients treated with FESS (1.48 ± 2.24, p = 0.04). Patients taking dupilumab were followed on average for 12.20 months and patients treated with FESS were followed for 17.90 months. CONCLUSION: Overall, both therapies are effective at reducing symptoms in patients with CRSwNP according to SNOT-22. Patients treated with dupilumab reported improved olfaction and decreased cough, postnasal drainage, and thick nasal drainage as compared with patients treated with FESS, while patients treated with FESS had a greater reduction in polyp burden.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Dharmarajan H, Falade O, Lee SE, et al. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022. PMID: 34919344. doi:10.1002/alr.22951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。